A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine SpikeVax, following in the footsteps of Pfizer/BioNTech, which filed their Comirnaty shot ...

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (NASDAQ: MRNA). The main reason for this week's decline is that Moderna lowered ...

Moderna's (MRNA) price target slashed to $38 from $70 by Morgan Stanley (MS), implying an 11% potential upside based on its last closing price. Analysts cite lowered 2025 revenue outlook and ...

One of the closest-to-market among the 10 is mRNA-1283, a next-generation COVID vaccine. In his Monday letter, Bancel said the FDA has accepted Moderna’s application for the shot. Assisted by a ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Moderna fell to a new 52-week low after some ... In addition, the company has 10 new products in its pipeline that it hopes will receive FDA approval within the next three years (including a ...